Table 1.

Association between Study Markers with Different Clinicopathological Characteristics in NSCLC Patients

	Variable	n	%	Serum miR-148a median (range)	P value	Serum Bcl-2 median (range)	P value
Gender	Male	44	88	0.5 (0.01 - 5.6)	0.56	2.5 (0.8 – 5.5)	0.87
	Female	6	12	0.7 (0.02 - 4.3)		2.4 (2.0 – 3.8)
Smoking Status	Yes	44	88	0.5 (0.01 – 5.6)	0.56	2.5 (0.8 – 5.5)	0.87
	No	6	12	0.7 (0.02 – 4.3)		2.4 (2.0 – 3.8)
Pathological Subtypes	Adenocarcinoma	26	52	0.4 (0.01 – 4.3)	0.095	2.8 (1.5 – 5.5)	0.085
	SCC	16	32	1.1 (0.01 – 5.6)		2.2 (0.8 – 4.6)
	Large Undifferentiated	8	16	0.3 (0.01 – 2.2)		2.6 (2.2 – 5.1)
Grade	I	3	6	2.8 (0.33 – 4.3)	0.353	2.1 (2.1 – 3.8)	0.725
	II	25	50	0.5 (0.01 – 5.6)		2.5 (0.8 – 5.5)
	III	22	44	0.5 (0.01 – 5.1)		2.5 (1.2 – 5.1)
Differentiation	Well	3	6	2.8 (0.33 – 4.3)	0.358	2.1 (2.1 – 3.8)	0.725
	Moderate	24	48	0.4 (0.01 – 5.6)		2.5 (0.8 – 5.5)
	Poor	23	46	0.6 (0.01 – 5.1)		2.5 (1.2 – 5.1)
Stage	I	12	24	2.9 (0.82 – 5.6)	<0.001*	2.0 (0.8 – 2.1)	<0.001*
	II	6	12	2.0 (0.74 – 2.3)		1.7 (1.5 – 2.3)
	III	25	50	0.3 (0.01 – 2.2)		2.7 (2.3 – 3.8)
	IV	7	14	0.1 (0.01 – 0.2)		4.3 (4.0 – 5.5
	Early stage (I + II)	18	36	2.3 (0.7 – 5.6)	<0.001*	1.9 (0.8 – 5.5)	<0.001*
	Late stage (III + IV)	32	64	0.2 (0.01 – 2.2)		3.2 (2.3 – 5.5)
Lymph Node Metastasis	Present	34	68	1.7 (0.05 – 5.6)	<0.001*	2.1 (0.8 – 3.8)	0.002*
	Absent	16	32	0.3 (0.01 – 2.3)		2.6 (1.5 – 5.5)
Distant Metastasis	Present	6	12	0.7 (0.01 – 5.6)	0.002*	2.4 (0.8 – 4.3)	<0.001*
	Absent	44	88	0.1 (0.01 – 0.2)		4.4 (4.0 – 5.5)

Qualitative data are represented as frequency (percentage); *P value <0.05 is significant; SCC, Squamous cell carcinoma.